Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Change in Accured Expenses (2019 - 2025)

Eton Pharmaceuticals' Change in Accured Expenses history spans 7 years, with the latest figure at $1.8 million for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 211.15% year-over-year to $1.8 million; the TTM value through Sep 2025 reached $2.6 million, up 222.45%, while the annual FY2024 figure was $1.5 million, 40.09% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $1.8 million at Eton Pharmaceuticals, up from $172000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $2.0 million in Q4 2024 and bottomed at -$1.6 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $368000.0 (2021), against an average of $321631.6.
  • The largest annual shift saw Change in Accured Expenses soared 4230.0% in 2023 before it tumbled 232.28% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $120000.0 in 2021, then plummeted by 153.33% to -$64000.0 in 2022, then soared by 2246.88% to $1.4 million in 2023, then surged by 48.69% to $2.0 million in 2024, then fell by 12.58% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Change in Accured Expenses are $1.8 million (Q3 2025), $172000.0 (Q2 2025), and -$1.4 million (Q1 2025).